Arbutus Biopharma Corporation ABUS
NASDAQ · United States · Health Technology
$4.56-0.22 (-4.60%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-08-12 | -0.03 | -0.02 | -50.0% | $1.01M | +44.9% | -1.9%$4.67→$4.58 |
| Q1 2026 | 2026-05-13 | 1.19 | -0.03 | +4,066.7% | — | — | +0.9%$4.31→$4.35 |
| Q4 2025 | 2026-03-23 | -0.01 | -0.05 | +80.0% | — | — | +1.7%$4.24→$4.31 |
| Q3 2025 | 2025-11-13 | -0.06 | -0.05 | -20.0% | — | — | -6.6%$4.84→$4.52 |
| Q2 2025 | 2025-08-06 | 0.01 | -0.09 | +111.1% | — | — | — |
| Q1 2025 | 2025-05-14 | -0.18 | -0.15 | -20.0% | — | — | — |
| Q4 2024 | 2025-03-27 | -0.10 | -0.12 | +16.7% | — | — | — |
| Q3 2024 | 2024-11-06 | -0.14 | -0.13 | -7.7% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.